Skip to main content
Premium Trial:

Request an Annual Quote

Julie Neidich

Pathway Genomics said that Julie Neidich has joined the firm as its new laboratory medical director. She joins the firm from GeneDx where she had served as clinical director of the whole exome sequencing program. Neidich has held faculty positions at Cornell University Medical College and Stanford University School of Medicine, as well as leadership roles at Quest Diagnostics-Nichols Institute and Ambry Genetics. She also was the founder of Global TeleGenetics.

She received her bachelor's degree from Bennington College and her doctorate from George Washington University, and she received pediatrics training at Albert Einstein College of Medicine-Montefiore Medical Center and genetics training at the Children's Hospital of Philadelphia-University of Pennsylvania.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.